Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brivanib+ Cetuximab · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Brivanib + Cetuximab | DRUG | Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks |
Inclusion Criteria: * Diagnosis of advanced or metastatic (tumor has spread) gastrointestinal malignancy * Feeling well other than cancer diagnosis (ie lab work, no infection, etc) * Available tumor tissue sample from prior surgery * Measurable disease on scans * 4-6 weeks since prior therapy and r...
Top 20 of 77 competitors
Brivanib is an investigational small molecule being studied for the treatment of solid tumors, hepatocellular carcinoma (HCC), liver cancer, and gastrointestinal cancers. It has been evaluated in clinical trials for these oncology indications, including advanced or metastatic solid tumors and hepatocellular carcinoma.
Brivanib is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company has sponsored clinical trials of Brivanib in patients with various cancers, including hepatocellular carcinoma and solid tumors.
Brivanib is an investigational drug that has completed Phase 1 and Phase 2 clinical trials. It is not approved by the FDA and remains in clinical development. All three completed trials were uncontrolled, meaning they did not include a comparison group.
Brivanib has been studied in three completed clinical trials. NCT00355238 was a Phase 2 study in hepatocellular carcinoma with 137 patients. NCT00390936 was a Phase 1 study in advanced solid tumors with 13 patients. NCT00437424 was a Phase 1 study in hepatocellular carcinoma with liver dysfunction, enrolling 24 patients.
Yes, Brivanib is also known as BMS-582664. Clinical trial records refer to the drug by both names, such as in the Phase 2 study of BMS-582664 in hepatocellular carcinoma and the Phase 1 study of Brivanib in liver cancer.